首页> 外文期刊>Expert opinion on therapeutic targets >Na+/K+-ATPase alpha subunits as new targets in anticancer therapy.
【24h】

Na+/K+-ATPase alpha subunits as new targets in anticancer therapy.

机译:Na + / K + -ATPaseα亚基作为抗癌治疗的新靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The sodium pump (Na(+)/K(+)-ATPase) could be a target for the development of anticancer drugs as it serves as a signal transducer, it is a player in cell adhesion and its aberrant expression and activity are implicated in the development and progression of different cancers. Cardiotonic steroids (CS) are the natural ligands and inhibitors of the sodium pump and this supports the possibility of their development as anticancer agents targeting overexpressed Na(+)/K(+)-ATPase alpha subunits. OBJECTIVES: To highlight and further develop the concept of using Na(+)/K(+)-ATPase alpha1 and alpha3 subunits as targets in anticancer therapy and to address the question of the actual usefulness of further developing CS as anticancer agents. CONCLUSIONS: Targeting overexpressed Na(+)/K(+)-ATPase alpha subunits using novel CS might open a new era in anticancer therapy and bring the concept of personalized medicine from aspiration to reality. Clinical data are now needed to further support this proposal. Furthermore, future medicinal chemistry should optimize new anticancer CS to target Na(+)/K(+)-ATPase alpha subunits with the aim of rendering them more potent and less toxic.
机译:背景:钠泵(Na(+)/ K(+)-ATPase)可能是抗癌药物开发的目标,因为它可以作为信号转导剂,它是细胞粘附的参与者,其异常表达和活性都很高。与不同癌症的发生和发展有关。心脏类固醇(CS)是钠泵的天然配体和抑制剂,这支持了它们作为靶向过表达的Na(+)/ K(+)-ATPaseα亚基的抗癌药发展的可能性。目的:突出并进一步发展使用Na(+)/ K(+)-ATPase alpha1和alpha3亚基作为抗癌治疗靶标的概念,并解决进一步开发CS作为抗癌剂的实际用途的问题。结论:使用新型CS靶向过度表达的Na(+)/ K(+)-ATPaseα亚基可能会开启抗癌治疗的新纪元,并将个性化医学的概念从理想变为现实。现在需要临床数据以进一步支持该建议。此外,未来的药物化学应优化新的抗癌药物CS,以靶向Na(+)/ K(+)-ATPaseα亚基,以使其更有效,毒性更小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号